Veracyte, Inc. (FRA:12V)
Germany · Delayed Price · Currency is EUR 41.00
+0.20 (0.49%)
At close: Nov 28, 2025
Veracyte Company Description
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.
Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte, Inc.
| Country | United States |
| Founded | 2006 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 824 |
| CEO | Marc Stapley |
Contact Details
Address: 6000 Shoreline Court South San Francisco, Delaware 94080 United States | |
| Phone | 650 243 6300 |
| Website | veracyte.com |
Stock Details
| Ticker Symbol | 12V |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Marc Stapley | Chief Executive Officer |
| Rebecca Chambers | Chief Financial Officer |
| Keith Gligorich | Chief Operating Officer |